Evaluation of Safety and Efficacy of Remifentanil in Pediatric Population
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Nov 22, 2011
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • preterm infants mechanically ventilated
- • requiring peripherally induced central catheterization
- • with informed consent of their parents
- Exclusion Criteria:
- • major congenital anomalies
- • cardiopulmonary instability
- • use of sedative, antiepileptic drugs or anesthetic drugs
- • grade III or IV intraventricular hemorrhage
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials